ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Related Videos
Eunice Wang, MD
Craig Sauter, MD
Lisa A. Carey MD, ScM, FASCO
Patrick I. Borgen, MD
Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)
Steven J. Chmura, MD, PhD
Kevin Kalinsky, MD, MS
Kelly K. Hunt, MD, FACS, FSSO
Laura J. Esserman, MD, MBA
Related Content